Transatlantic Rebuffs Berkshire Hathaway

Transatlantic Holdings rebuffed Berkshire Hathaway’s cash bid of $3.25 billion, ensuring the deal would expire by market close on Monday.

Berkshire Hathaway informed Transatlantic on Friday that its offer of $52 per share would not increase. However, Transatlantic said in a statement that Berkshire’s “opportunistic” bid is far below its value of nearly $70 per share.

Berkshire Hathaway Inc.

The death of the Berkshire deal marks the end of another merger opportunity for Transatlantic, which canceled its proposed merger with Allied World Alliance last Friday amid shareholder opposition.

Validus Holdings is the only remaining bidder at the table, as it pursues a hostile stock-and-cash bid bid worth $47.41 per share or $2.96 billion. As part of its negotiations, Validus is attempting to replace Transatlantic’s Board of Directors to leverage its position.

Transatlantic is a holding company which provides fire, marine, and casualty insurance through its subsidiary companies.

Osterweis Capital Management, managed by John Osterweis, decreased their position in Transatlantic by 3% last quarter, which brought them to nearly 2 million shares.

Here are the top hedge funds with positions in Transatlantic Holdings.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!